Tirzepatide: Research Uses, Reconstitution, and Safe Laboratory Handling
Reviewed by the VendPeptides Editorial Team. Written from product labeling, the batch certificate of analysis and published literature. Last updated September 2026.
Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist peptide supplied as a lyophilized powder for laboratory research.
It has been studied in published preclinical and clinical literature, including the SURMOUNT-1 phase 3 trial, as a dual incretin receptor agonist.
It is also known by the code name LY3298176 and the brand names Mounjaro and Zepbound, and it is sold here in single vials and 10-vial bulk kits ranging from 5 mg to 60 mg per vial.
This guide covers what Tirzepatide is, how to calculate reconstitution concentrations by vial size, safe laboratory handling, and where to buy research-grade material.
What is Tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist at the GIP and GLP-1 receptors, with CAS number 2023788-19-2.
In the research literature it is described as a dual incretin receptor agonist, and its activity at both receptors is the property most often examined in mechanistic studies.
VendPeptides supplies Tirzepatide as a sterile-filtered, lyophilized powder in single vials and 10-vial bulk kits, with batch certificates of analysis available for every lot.
For research purposes only. Not for human consumption.
Tirzepatide, LY3298176 and Mounjaro: are they the same?
Yes. LY3298176 is the internal development code used by the originator during discovery and early trials, and Mounjaro and Zepbound are the brand names under which the same molecule is marketed; all refer to the same peptide sequence.
The practical difference for a laboratory is the presentation: research-grade lyophilized vials from a supplier such as VendPeptides are labeled for laboratory use only, while brand-name pharmaceutical products are approved medicines with their own regulatory status.
When comparing literature, check whether a paper refers to the compound by code name, by generic name, or by brand name, because the underlying molecule is identical.
For research purposes only. Not for human consumption.
What has Tirzepatide been studied for?
Tirzepatide has been studied in published research on dual GIP/GLP-1 receptor agonism, including the SURMOUNT-1 phase 3 trial reported in the New England Journal of Medicine in 2022.
The published literature describes its receptor binding profile, pharmacokinetic behavior in animal models, and metabolic endpoints; those reports are the appropriate reference for what has been examined, not any claim made by a supplier.
Tirzepatide as sold by VendPeptides is a research chemical and is not approved for any medical or veterinary purpose.
It is not for human or animal use, and no statement here should be read as a description of an outcome, benefit, or intended use.
For research purposes only. Not for human consumption.
Always read the vial label and the batch certificate of analysis (COA) before using any lot, and consult the primary literature for study design and findings.
Tirzepatide reconstitution and concentration by vial size
Adding 1 mL of bacteriostatic water to a 5 mg vial gives 5 mg/mL, and the same arithmetic scales to every vial size sold.
| Vial size | 10-vial kit total | Diluent added | Resulting concentration | µg per µL |
|---|---|---|---|---|
| 5 mg | 50 mg | 1 mL (1,000 µL) | 5 mg/mL | 5 µg/µL |
| 10 mg | 100 mg | 1 mL (1,000 µL) | 10 mg/mL | 10 µg/µL |
| 15 mg | 150 mg | 1.5 mL (1,500 µL) | 10 mg/mL | 10 µg/µL |
| 20 mg | 200 mg | 2 mL (2,000 µL) | 10 mg/mL | 10 µg/µL |
| 30 mg | 300 mg | 3 mL (3,000 µL) | 10 mg/mL | 10 µg/µL |
The vial label and the batch certificate of analysis take priority over any table; if the label states a different fill or diluent volume, follow the label.
Tirzepatide 10mg vial reconstitution
Adding 1 mL (1,000 µL) of bacteriostatic water to a 10 mg vial yields 10 mg/mL, which is 10 µg/µL.
If a lower working concentration is preferred, add 2 mL (2,000 µL) instead to obtain 5 mg/mL, or 5 µg/µL.
Add the diluent slowly down the inside wall of the vial rather than onto the powder, then swirl; do not shake, because agitation can denature the peptide.
For research purposes only. Not for human consumption.
Tirzepatide 5mg vial reconstitution
Adding 1 mL (1,000 µL) of bacteriostatic water to a 5 mg vial yields 5 mg/mL, which is 5 µg/µL.
This is the smallest single-vial size sold and is often used when a small working quantity is needed for a single experiment.
Record the diluent volume, date, and lot number on the vial label immediately after reconstitution.
For research purposes only. Not for human consumption.
How long does reconstituted Tirzepatide stay stable?
There is no single published stability figure that applies to every lot; the batch certificate of analysis and the vial label are the controlling references for storage and handling.
As general laboratory practice, reconstituted peptide solutions are kept refrigerated and protected from light, and repeated freeze-thaw cycles are avoided.
See the Peptide Storage Guide: Temperature, Light and Freeze-Thaw for a fuller discussion of storage variables.
How to handle Tirzepatide safely in the laboratory
- Read the vial label and the batch certificate of analysis before opening the vial, and confirm the lot number matches your records.
- Put on a lab coat, nitrile gloves, and eye protection, and work in a ventilated area or biosafety cabinet.
- Inspect the lyophilized cake for discoloration or moisture before adding any diluent, and quarantine the vial if either is present.
- Wipe the stopper with a fresh alcohol swab and let it dry before inserting any transfer device.
- Add bacteriostatic water slowly down the vial wall, then swirl gently until the powder is fully dissolved; never vortex or shake.
- Label the reconstituted vial with the concentration, diluent, date, and your initials, and log it in the laboratory notebook.
- Store the vial according to the label and COA, and dispose of unused material and sharps in the designated laboratory waste streams.
Warning: Poor sterile technique or an unlabeled vial is the most common source of contamination and mix-ups in peptide work, so swab every stopper, use a fresh transfer device, and label the vial before you set it down.
Is Tirzepatide the same as Retatrutide?
No. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Retatrutide is a triple agonist studied for activity at the GIP, GLP-1, and glucagon receptors.
They are distinct molecules with distinct CAS numbers, distinct receptor profiles, and separate published literatures, so data from one should not be assumed to apply to the other.
If your experiment compares them, treat each as its own lot with its own certificate of analysis.
For research purposes only. Not for human consumption.
Is Tirzepatide safe for humans?
No. Tirzepatide sold by VendPeptides is a research chemical and is not approved for any medical or veterinary purpose.
It is not for human consumption, and it must not be used in humans under any circumstances.
The FDA has published general guidance on research chemicals and 'not for human consumption' labeling; that guidance applies to this material.
For research purposes only. Not for human consumption.
Can Tirzepatide be used for pets or animals?
No. This product is supplied for laboratory research only and is not a veterinary product.
It is not approved for any medical or veterinary purpose, and it is not for animal use.
If you have a question about the health of an animal, consult a licensed veterinarian.
For research purposes only. Not for human consumption.
Where to buy Tirzepatide (5 mg to 60 mg)
VendPeptides ships Tirzepatide from a US warehouse as Tirzepatide Single Vial in 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg strengths, and as the Tirzepatide 10-Vial Bulk Kit TR with kit totals from 50 mg to 600 mg.
Single-vial pricing runs from $36.00 for 5 mg to $245.00 for 60 mg, and bulk kit pricing runs from $310.00 for the 50 mg kit to $1,200.00 for the 600 mg kit.
Every label carries the batch certificate of analysis and expiry information, and the COA is the reference to check before use.
Related research materials in the same catalog include the Metabolic Research Peptides collection, the Retatrutide 10-Vial Bulk Kit RT from $380.00, and the Semaglutide 10-Pack Kits SM from $235.00.
For research purposes only. Not for human consumption.
Frequently asked questions
Is Tirzepatide safe for humans?
No. It is sold as a research chemical, is not approved for any medical or veterinary purpose, and is not for human consumption.
Is Tirzepatide the same as Retatrutide?
No. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Retatrutide is a triple agonist studied at the GIP, GLP-1, and glucagon receptors; they are different molecules with separate literatures.
How do I reconstitute a 10mg Tirzepatide vial?
Add 1 mL (1,000 µL) of bacteriostatic water down the vial wall to obtain 10 mg/mL, or 10 µg/µL; add 2 mL (2,000 µL) if you want 5 mg/mL. Swirl gently and never shake, then label the vial with concentration, diluent, date, and lot.
Can Tirzepatide be used for pets or animals?
No. It is for laboratory research only, is not a veterinary product, and is not for animal use; consult a licensed veterinarian for any animal health question.
Is Tirzepatide the same as Mounjaro or Zepbound?
The active molecule is the same, but the presentations differ: Mounjaro and Zepbound are approved pharmaceutical products, while the vials sold here are research-grade material labeled for laboratory use only. For research purposes only. Not for human consumption.
Is Tirzepatide a peptide, and what class is it?
Yes. It is a synthetic peptide and is classified as a dual GIP/GLP-1 receptor agonist, with CAS number 2023788-19-2 and the code name LY3298176.
Can you still buy Tirzepatide?
Yes. VendPeptides ships Tirzepatide single vials and 10-vial bulk kits from a US warehouse, with batch COA and expiry information on every label. For research purposes only. Not for human consumption.
Sources and further reading
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022.
- FDA — Mounjaro (tirzepatide) approval information
- PubChem — Tirzepatide
Disclaimer. This article is educational and describes laboratory handling and published literature only. It is not medical or veterinary advice and is not a substitute for a licensed professional. For research purposes only. Not for human consumption. Products are sold to qualified researchers for in-vitro and laboratory research, are not approved drugs, foods, cosmetics or devices, and are not for human or animal use. This article was written with AI assistance and reviewed by a member of the VendPeptides Editorial Team.